List of Excipients in Branded Drug PURINETHOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Stason Pharmaceuticals Inc	PURINETHOL	mercaptopurine	60763-601	LACTOSE MONOHYDRATE
Stason Pharmaceuticals Inc	PURINETHOL	mercaptopurine	60763-601	MAGNESIUM STEARATE
Stason Pharmaceuticals Inc	PURINETHOL	mercaptopurine	60763-601	STARCH, CORN

PURINETHOL Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Purinethol is the branded tablet formulation of mercaptopurine, an oral purine antimetabolite used primarily in acute lymphoblastic leukemia maintenance therapy. The active pharmaceutical ingredient is generic and chemically old, so commercial value is concentrated in formulation performance, pediatric usability, supply reliability, and regulatory execution rather than in core compound exclusivity.

The strongest excipient opportunity is a differentiated oral liquid that improves dose flexibility, palatability, redispersibility, chemical stability, and handling safety. Purixan, a 20 mg/mL mercaptopurine oral suspension, already occupies this segment in the United States, which raises the entry threshold but also validates demand for liquid delivery. [1][2]

What is Purinethol and which excipients does it contain?

Purinethol contains mercaptopurine, also known as 6-mercaptopurine or 6-MP. The United States product is a 50 mg oral tablet. The tablet formulation uses conventional solid-dose excipients, including lactose, starch, and stearic acid, according to product labeling and international product information. [1][3]

Attribute	Purinethol
Active ingredient	Mercaptopurine
Chemical designation	6-Mercaptopurine
Drug class	Purine antimetabolite
Dosage form	Immediate-release tablet
Strength	50 mg
Primary use	Maintenance treatment of acute lymphoblastic leukemia
Administration	Oral
Core formulation	Conventional compressed tablet
Pediatric need	Weight- or body-surface-area-based dosing
Key formulation issue	Accurate fractional dosing and administration in children

Mercaptopurine has low aqueous solubility and presents dose-management challenges in pediatric patients. Treatment is often individualized by body surface area, blood counts, hepatic function, thiopurine metabolism, and concomitant therapy. A fixed 50 mg tablet can require tablet splitting, dose rounding, or extemporaneous manipulation.

What excipients are used in Purinethol tablets?

Purinethol’s conventional excipient system supports tablet compression and physical integrity rather than providing a differentiated delivery profile.

Lactose

Lactose is commonly used as a diluent and contributes to tablet mass and compactability. Its commercial advantages are low cost, broad regulatory familiarity, and established supply. Its disadvantages include suitability concerns for patients with lactose intolerance and potential incompatibility concerns in some formulations involving reactive drug substances or high-moisture processing.

For mercaptopurine, lactose-free positioning could support a differentiated generic or pediatric product, but lactose removal alone would have limited commercial value unless combined with improved dose flexibility or tolerability.

Starch

Starch can act as a filler, disintegrant, or binder depending on grade and processing method. It supports rapid tablet breakup and is compatible with low-cost direct-compression or wet-granulation platforms.

A formulation using pregelatinized starch or a more efficient superdisintegrant could improve tablet robustness while reducing tablet size. That would matter most for pediatric tablets or lower-strength products.

Stearic acid

Stearic acid is used as a lubricant. Lubricant level and blending time require control because excessive lubrication can reduce tablet tensile strength or delay disintegration.

Excipient strategy assessment

Formulation objective	Conventional Purinethol approach	Potential improvement
Tablet compression	Lactose and starch-based system	Direct compression with optimized co-processed excipient
Disintegration	Starch	Superdisintegrant or fast-disintegrating platform
Dose flexibility	50 mg tablet	10 mg, 25 mg, scored, dispersible, or multiparticulate format
Pediatric administration	Tablet swallowing or manipulation	Oral suspension, dispersible tablet, or mini-tablet
Palatability	No major taste-masking architecture	Ion exchange resin, coating, complexation, or flavor system
Stability	Conventional solid-state protection	Moisture-control packaging and suspension stabilizer system
Adherence	Fixed tablet strength	Dosing syringe and flexible concentration

What formulation patents protect mercaptopurine products?

The original compound and early Purinethol formulation rights are long expired. Mercaptopurine was developed decades ago, and the active ingredient does not have meaningful new-molecule patent protection in current markets.

Commercially relevant protection may instead attach to:

• Oral suspension composition and physical stability.
• Taste-masking systems.
• Dosing devices and administration kits.
• Specific particle-size distributions.
• Manufacturing processes.
• Container-closure systems.
• Preservative systems.
• Pediatric dosage forms.
• Ready-to-use or ready-to-dispense presentations.

The most important current formulation precedent is Purixan, a 20 mg/mL oral suspension. FDA labeling identifies the product as an oral suspension for pediatric and adult use, with a supplied oral dosing syringe and product-specific administration instructions. [2]

A competitor should not assume that the absence of compound patents means unrestricted freedom to operate. Formulation and device claims can create narrower barriers even where the active ingredient is public domain. Patent scope must be reviewed against the current United States Patent and Trademark Office records, FDA Orange Book listings, and any applicable litigation filings.

When does Purinethol lose exclusivity?

Purinethol’s regulatory and compound exclusivity has expired. Mercaptopurine is an established generic active ingredient, and multiple manufacturers have supplied mercaptopurine tablets in the United States and other markets.

The practical exclusivity position is:

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Original compound patent	Expired
Orphan exclusivity	No current exclusivity associated with the old tablet product
Pediatric exclusivity	Any historical period has expired
Tablet formulation exclusivity	No broad current exclusivity apparent from the product’s age and generic availability
Oral suspension differentiation	Potentially protected through formulation, device, trademark, or regulatory barriers
Biosimilar exclusivity	Not applicable

Because Purinethol is a small-molecule drug, biosimilar competition is not relevant. Competitive entry occurs through ANDA products, authorized generics, compounding, or differentiated formulations.

What is the FDA regulatory status of Purinethol and mercaptopurine liquids?

Purinethol is regulated as a prescription drug. Mercaptopurine tablets are available as generic products through the abbreviated new drug application pathway. FDA-approved liquid competition exists in the form of Purixan oral suspension. [1][2]

Regulatory routes for a new excipient strategy

ANDA tablet

An ANDA is the lowest-risk route for a conventional mercaptopurine tablet that matches the reference product in dosage form, strength, route, and performance. Commercial differentiation is limited unless the product has a lower cost structure, superior supply, or additional strengths.

505(b)(2) oral liquid

A 505(b)(2) application is more suitable for a novel oral suspension, dispersible tablet, or other formulation that relies partly on published information or an established reference product but introduces a meaningful formulation change.

A 505(b)(2) product could seek differentiation through:

• Improved pediatric dosing.
• Reduced dosing errors.
• Better taste.
• Longer in-use stability.
• Easier storage.
• Lower sedimentation.
• Lower microbial risk.
• Reduced need for shaking.
• Improved compatibility with feeding tubes.

Compounded preparation

Compounded mercaptopurine suspensions may fill local access gaps but do not provide the same scale, quality assurance, stability package, or reimbursement position as an FDA-approved product. A commercial product can compete by offering standardized concentration, validated stability, and a calibrated oral syringe.

What excipient platforms offer the strongest commercial opportunity?

1. Pediatric oral suspension

A 20 mg/mL suspension is commercially validated by Purixan. A new entrant would need a measurable advantage in price, supply, palatability, stability, or distribution.

The formulation should address:

• Uniform dose delivery after shaking.
• Minimal sedimentation and caking.
• Chemical stability over the labeled shelf life.
• Short-term in-use stability.
• Preservative effectiveness.
• Low viscosity sufficient for oral syringe dosing.
• Flavor acceptance without excessive sweetness.
• Compatibility with common oral syringes and feeding tubes.

Potential excipient classes include suspending polymers, wetting agents, buffers, sweeteners, flavors, preservatives, and antifoaming agents. The key technical constraint is balancing suspension stability with syringeability. Excessive viscosity can improve physical stability while reducing dosing accuracy and patient acceptability.

2. Taste-masked pediatric dispersible tablet

Mercaptopurine has an unpleasant taste profile that can reduce adherence when tablets are crushed or dispersed. A dispersible tablet could use taste-masking through polymer coating, lipid coating, ion exchange, or multiparticulate encapsulation.

This platform may offer better chemical stability than a liquid and lower shipping cost. It also could reduce the need for preservatives. The main development risks are rapid drug release after dispersion, incomplete transfer from a dosing cup, and variability in dose recovery.

3. Mini-tablets

Mini-tablets can provide a solid-dose option for children who cannot swallow a 50 mg tablet. Strengths such as 5 mg, 10 mg, or 25 mg could support individualized dosing while avoiding liquid preservatives and flavor systems.

Mini-tablets require tight control of content uniformity, segregation, friability, and packaging. A unit-dose blister or sachet presentation could reduce handling errors.

4. Lower-strength scored tablets

A 10 mg or 25 mg tablet could compete directly with the dose-flexibility problem created by the 50 mg Purinethol tablet. The product would have a simpler regulatory profile than a novel liquid but less differentiation from generic competitors.

5. Excipient-free or low-excipient formulations

Reducing excipient count could appeal to patients with allergies or intolerance, but the commercial value is limited unless the product solves a specific problem. An excipient-minimized tablet must still meet dissolution, stability, manufacturability, and content-uniformity requirements.

How strong is the mercaptopurine patent estate?

The compound patent estate is weak because mercaptopurine is an old active ingredient. The potentially stronger rights are formulation-specific and narrow.

Patent category	Relative strength	Commercial relevance
Mercaptopurine compound claims	Very low	Expired
Conventional 50 mg tablet	Low	Generic competition
Novel oral suspension	Moderate	Depends on claim scope and expiration
Taste-masked pediatric dosage form	Moderate	Potentially valuable if clinically differentiated
Dosing syringe or administration system	Low to moderate	Device and combination claims may matter
Manufacturing process	Low to moderate	Can raise switching costs if difficult to design around
Stability-enhanced formulation	Moderate	Relevant where it produces longer shelf life or in-use stability

A liquid formulation patent is strongest when it claims a defined composition tied to measurable performance, such as sedimentation behavior, redispersibility, preservative stability, particle-size control, or chemical degradation limits. Broad claims to "a mercaptopurine suspension" are more vulnerable to prior art and design-around strategies.

What generic entry risks exist for Purinethol and Purixan?

Purinethol tablet entry

Generic entry risk is high because the product is old, the active ingredient is well characterized, and the dosage form is conventional. Price erosion is likely where multiple tablet suppliers compete.

The principal commercial defenses are:

• Reliable supply during shortages.
• Lower manufacturing cost.
• Multiple strengths.
• Institutional contracts.
• Pediatric packaging.
• Distribution relationships.
• Product quality and recall avoidance.

Purixan-type liquid entry

Liquid entry risk is more complex. A competitor must overcome formulation development and regulatory hurdles, but the market is smaller and the incumbent product has a differentiated presentation.

Potential entry routes include:

1. A therapeutically equivalent oral suspension.
2. A 505(b)(2) liquid with improved stability or palatability.
3. A dispersible tablet.
4. A lower-cost product using a different excipient architecture.
5. A compounding or hospital-focused presentation.

A competing liquid does not automatically create substitutability if the product has different concentration, dosing instructions, storage conditions, preservatives, or device requirements.

What is the Orange Book status of Purinethol?

Purinethol and approved mercaptopurine products should be reviewed in the current FDA Orange Book for active listings, reference-product designation, patents, and exclusivity entries. [4]

The commercial interpretation is straightforward:

• The old tablet product is exposed to generic competition.
• Orange Book-listed patents, if any, must be assessed at the product level rather than inferred from the age of mercaptopurine.
• Oral suspension products may have separate patents, labeling, and reference-product positions.
• A formulation patent can affect an ANDA applicant only if it is listed and legally enforceable against the proposed product.

Orange Book status can change through patent delisting, expiration, product discontinuation, or FDA database updates. Product-specific review is required before a Paragraph IV strategy or launch decision.

Which companies are challenging or competing with Purinethol?

Competition comes from generic manufacturers of mercaptopurine tablets and from specialized suppliers of oral liquids.

The competitive field includes:

• Generic tablet manufacturers.
• Authorized generic suppliers.
• Specialty pharmaceutical companies with pediatric liquids.
• Hospital and pharmacy compounders.
• Contract manufacturers with oral suspension capabilities.

No biosimilar companies are relevant because mercaptopurine is a synthetic small molecule, not a biologic.

Publicly reported product-level revenue for Purinethol is generally limited. Revenue exposure is better estimated from prescription volume, institutional purchasing, oncology distribution, reimbursement, and liquid-versus-tablet mix than from standalone company disclosures.

What licensing deals and settlement agreements affect mercaptopurine?

No major current licensing or Paragraph IV settlement agreement is central to the commercial positioning of the legacy Purinethol tablet. The important transaction pattern is more likely to involve:

• Distribution rights for pediatric liquids.
• Regional commercialization agreements.
• Contract manufacturing.
• Licensing of taste-masking or suspension technology.
• Device supply agreements for oral syringes.
• Hospital access contracts.

Any transaction involving an oral suspension should include freedom-to-operate review for composition, process, device, trademark, and regulatory exclusivity rights.

What manufacturing and IP barriers matter most?

The manufacturing barrier for tablets is low. Standard blending, granulation, compression, coating, and packaging equipment can produce mercaptopurine tablets.

The liquid barrier is higher because the manufacturer must control:

• Particle-size distribution.
• Wetting and deagglomeration.
• Suspension uniformity.
• Sedimentation and redispersion.
• Microbial control.
• Preservative performance.
• Chemical degradation.
• Fill-volume accuracy.
• Oral syringe compatibility.
• Cleaning validation for a cytotoxic or hazardous active ingredient.

Mercaptopurine handling also creates occupational and facility requirements. Containment, dedicated procedures, cleaning validation, and cross-contamination controls can increase manufacturing cost. These operational barriers may be more important than patent barriers for a smaller liquid entrant.

How does Purinethol compare with competing mercaptopurine formulations?

Product type	Strengths	Weaknesses	Commercial opportunity
50 mg tablet	Low cost, stable, simple manufacturing	Poor pediatric dose flexibility	Commodity supply and lower-strength tablets
Generic tablet	Price competition and broad access	Limited differentiation	Cost leadership and supply reliability
20 mg/mL oral suspension	Flexible dosing, pediatric usability	Taste, stability, preservation, higher cost	Strongest formulation opportunity
Dispersible tablet	Solid-state stability, no preservative requirement	Taste and dose recovery concerns	Pediatric specialty product
Mini-tablet	Accurate unit dosing, portable	More complex manufacturing and packaging	Niche pediatric and adherence market
Compounded suspension	Local flexibility	Variable quality and short beyond-use periods	Limited to access gaps

What generic launch scenarios are commercially realistic?

Scenario 1: Low-cost tablet launch

This is the fastest route but has the lowest differentiation. Success depends on manufacturing economics, supply continuity, and payer or wholesaler access.

Scenario 2: Lower-strength tablet launch

A 10 mg or 25 mg tablet can address pediatric dosing without competing solely on the 50 mg tablet price. The market remains limited unless the product is adopted by oncology centers and specialty pharmacies.

Scenario 3: Competing oral suspension

This offers the highest potential value but requires formulation, device, stability, microbiology, and regulatory investment. A new liquid must offer a clear advantage over the existing 20 mg/mL product.

Scenario 4: Premium pediatric platform

A taste-masked, unit-dose, dispersible or mini-tablet product could command specialty pricing if it improves adherence and reduces dosing errors. Clinical evidence would strengthen the commercial case but increase development cost.

Key Takeaways

• Purinethol is an old mercaptopurine tablet product with no meaningful remaining compound exclusivity.
• Conventional tablet excipients create limited differentiation and high generic-entry risk.
• The strongest commercial opportunity is pediatric dose flexibility, especially through an oral suspension, dispersible tablet, mini-tablet, or lower-strength tablet.
• Purixan validates demand for a 20 mg/mL mercaptopurine suspension but raises the competitive threshold for a new liquid.
• Formulation patents, device claims, and process know-how matter more than compound patents.
• Biosimilar risk is irrelevant; generic and specialty-formulation competition are the relevant threats.
• Manufacturing containment and liquid stability may create greater practical barriers than patent protection.
• A commercially credible entrant needs a measurable advantage in palatability, stability, dosing accuracy, supply, or cost.

FAQs

Can mercaptopurine tablets be reformulated without a new patent?

Yes. A reformulation can be developed without obtaining a new patent, but patent protection may be available for a novel composition, process, delivery system, or stability profile.

Is a mercaptopurine oral suspension eligible for an ANDA?

Eligibility depends on whether the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to an FDA-designated reference product. A materially different formulation or concentration may require a 505(b)(2) pathway.

What is the best preservative strategy for mercaptopurine suspension?

The preservative system must be selected through compatibility, antimicrobial effectiveness, degradation, container-closure, and in-use stability studies. No single preservative is universally optimal.

Can a taste-masked mercaptopurine product obtain pediatric market exclusivity?

A product may qualify for pediatric exclusivity only through the FDA pediatric-study framework and applicable statutory requirements. Taste masking alone does not create exclusivity.

Does a new mercaptopurine liquid need a new dosing device?

Not always, but a calibrated oral syringe can improve dose accuracy and support product differentiation. Device compatibility and dosing instructions should be established as part of the product design.

References

1. U.S. Food and Drug Administration. (n.d.). Purinethol: Mercaptopurine tablet prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Purixan: Mercaptopurine oral suspension prescribing information.
3. Electronic Medicines Compendium. (n.d.). Puri-Nethol 50 mg tablets: Summary of product characteristics.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.